Literature DB >> 22189620

Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: Bonica lecture, ASRA 2010.

Srinivasa N Raja1.   

Abstract

This article provides a brief overview of earlier work of our group on the peripheral signaling of pain, summarizes more recent studies on the role of opioids in chronic neuropathic pain, and speculates on the future of gene-based therapies as novel strategies to enhance the peripheral modulation of pain. Neurophysiologic and psychophysical studies have revealed features of primary afferent activity from somatic tissue that led to improved understanding of the physiology and pathophysiology of pain signaling by nociceptive and nonnociceptive fibers. The demonstration of peripheral opioid mechanisms in neuropathic pain suggests a potential role for these receptors in the modulation of pain at its initiation site. Our work has focused on characterizing this peripheral opioid analgesia in chronic neuropathic pain such that it can be exploited to develop novel and potent peripheral analgesics for its treatment. Ongoing research on virus-mediated gene transfer strategies to enhance peripheral opioid analgesia is presented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22189620      PMCID: PMC3288690          DOI: 10.1097/AAP.0b013e31823b145f

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  56 in total

1.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Prescription drug abuse: an epidemic dilemma.

Authors:  Robert L DuPont
Journal:  J Psychoactive Drugs       Date:  2010-06

Review 3.  Topical capsaicin for chronic neuropathic pain in adults.

Authors:  Sheena Derry; Rosalind Lloyd; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

4.  Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain.

Authors:  Zahid Ali; Srinivasa N Raja; Ursula Wesselmann; Perry N Fuchs; Richard A Meyer; James N Campbell
Journal:  Pain       Date:  2000-11       Impact factor: 6.961

5.  Mu and delta opioid receptors on nociceptors attenuate mechanical hyperalgesia in rat.

Authors:  E K Joseph; J D Levine
Journal:  Neuroscience       Date:  2010-08-22       Impact factor: 3.590

6.  Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury.

Authors:  Chun-Yi Lee; Federico M Perez; Wei Wang; Xiaowei Guan; Xiuli Zhao; Janet L Fisher; Yun Guan; Sarah M Sweitzer; Srinivasa N Raja; Yuan-Xiang Tao
Journal:  Eur J Pain       Date:  2011-02-09       Impact factor: 3.931

7.  Gene therapy for pain: results of a phase I clinical trial.

Authors:  David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe
Journal:  Ann Neurol       Date:  2011-07-27       Impact factor: 10.422

Review 8.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

Review 9.  Peripheral opioid receptor agonists for analgesia: a comprehensive review.

Authors:  Nalini Vadivelu; Sukanya Mitra; Roberta L Hines
Journal:  J Opioid Manag       Date:  2011 Jan-Feb

Review 10.  Neuropathic pain: models and mechanisms.

Authors:  Michael F Jarvis; Janel M Boyce-Rustay
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more
  2 in total

Review 1.  [Pain inhibition by opioids-new concepts].

Authors:  C Stein
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

2.  Targeting pain and inflammation by peripherally acting opioids.

Authors:  Christoph Stein
Journal:  Front Pharmacol       Date:  2013-09-23       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.